Anthropic and Novartis are collaborating on preclinical drug discovery programs, while the rivalry between AI firms drives market focus.
Steady: 0 in the last 7 days
Updated sep 23
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Anthropic and Novartis are collaborating on preclinical drug discovery programs, while the rivalry between AI firms drives market focus.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Novartis CEO joined Anthropic's board.Sub-event
Anthropic partners with Novartis for drug discovery, amid ongoing AI industry rivalry.1 source
Keep exploring
The entities involved
-
Anthropic
American artificial intelligence corporation
-
Novartis
Swiss-American multinational pharmaceutical corporation
-
OpenAI
American artificial intelligence research organization
- AMD is gaining significant market share in the AI infrastructure race through major GPU commitments from OpenAI and Meta, supported by partners like ZT Systems.
- SoftBank's investment portfolio performance is currently being assessed against the backdrop of the broader AI market sentiment and its impact on key technology companies.
Related events
- The competitive landscape of advanced AI is highlighted by the race among major labs (OpenAI, Google, Anthropic) to build powerful models and the movement of key researchers.
- AI labs are improving personalized medicine treatments, prompting FDA requirements for human proof points in drug approval.
- Medicine and university researchers are participating in Anthropic's AI program.
- Microsoft AI is testing its models with Meta and DeepSeek, joining Google and OpenAI in AI claims.